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Abstract
Post-Traumatic Stress Disorder is a mental health condition brought on by witnessing or 
experiencing distressing or terrifying events. Both MDMA and SSRIs like fluoxetine have 
shown to aid in fear extinction and clinical recovery from PTSD. However, recent studies have 
shown that MDMA used alongside therapy may have longer lasting effects on the anxiety 
symptoms of PTSD and can result in quicker fear extinction responses compared to current 
therapeutic methods using SSRIs. This review analyzes the knowledge and studies available 
comparing the efficacy of MDMA-Assisted psychotherapy to traditional psychotherapy in 
treating anxiety-related symptoms of PTSD in adults aged 18 to 40.
Introduction
• PTSD
• PTSD is a mental health condition brought on by witnessing or experiencing 
distressing or terrifying events
• Symptoms of PTSD can be devastating and contribute to increased suicidality
• Even with treatment, relapse is not uncommon. Of those who continued 
traditional psychotherapy, 16.4% had relapsed after 24-28 weeks of treatment
• MDMA-Assisted Psychotherapy
• MDMA, or 3,4-methylenedioxymethamphetamine, is a psychoactive chemical 
which stimulates the release of serotonin, oxytocin, prolactin, and cortisol
• Up until it became a Schedule I drug in 1985, MDMA was used as in 
therapeutic settings.
• Researchers have further hypothesized that MDMA-Assisted Psychotherapy 
has a stronger, longer lasting effect on reducing these symptoms of PTSD than 
the traditional therapies used today
Methods
• Performed November 2019
• EBSCO, Google Scholar, and Google
• Search Terms: “mdma-assisted psychotherapy” or “mdma assisted psychotherapy for ptsd
traditional therapy” or “mdma-assisted psychotherapy randomized controlled trial” or 
“How does the efficacy of MDMA-Assisted Psychotherapy compare to the efficacy in 
traditional psychotherapy in treating 18-40 year old adults diagnosed with Post-Traumatic 
Stress Disorder (PTSD)”
• Inclusion criteria
• Peer reviewed and/or Scholarly
• Published in 2013 or later
• Discusses at least one of the following:
• The effects of MDMA-assisted psychotherapy on PTSD
• The effects of MDMA-assisted psychotherapy on anxiety
• The pharmacodynamics of MDMA and how it can be used in 
treatment for mental illness
• Comparing MDMA-assisted psychotherapy to traditional 
psychotherapy
• Exclusion criteria
• Articles which were not peer reviewed or scholarly
• Articles which simply support or critique a previously chosen article without 
providing new information regarding the PICO question
• Articles which were written before 2013
• Articles that did not fit any of the inclusion criteria listed above
Results
1. Danforth AL, Grob CS, Struble C, et al. Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-
blind, placebo-controlled pilot study. Psychopharmacology. 2018;235(11):3137-3148. doi:10.1007/s00213-018-5010-9.
1. RCT of 12 participants followed by open crossover after 1 month comparing the efficacy of placebo-assisted psychotherapy to MDMA-Assisted 
psychotherapy in reducing anxiety symptoms
2. Wagner MT, Mithoefer MC, Mithoefer AT, et al. Therapeutic effect of increased openness: Investigating mechanism of action in MDMA-assisted 
psychotherapy. Journal of Psychopharmacology. 2017;31(8):967-974. doi:10.1177/0269881117711712.
1. RCT of 20 participants followed by open crossover after 2 months comparing the efficacy of placebo-assisted psychotherapy to MDMA-Assisted 
psychotherapy in treating PTSD
3. Oehen P, Traber R, Widmer V, Schnyder U. A randomized, controlled pilot study of MDMA (±3,4-Methylenedioxymethamphetamine)-assisted 
psychotherapy for treatment of resistant, chronic Post-Traumatic Stress Disorder (PTSD). Journal of Psychopharmacology. 2013;27(1):40-52. 
doi:10.1177/0269881112464827.
1. RCT of 14 participants followed by “active placebo condition” comparing the efficacy of placebo-assisted psychotherapy to MDMA-Assisted 
psychotherapy in treating PTSD
4. Amoroso T, Workman M. Treating posttraumatic stress disorder with MDMA-assisted psychotherapy: A preliminary meta-analysis and comparison to 
prolonged exposure therapy. Journal of Psychopharmacology. 2016;30(7):595-600. doi:10.1177/0269881116642542.
1. Meta-analysis of RCTs with 712 total participants comparing the efficacy of prolonged exposure therapy to MDMA-Assisted Psychotherapy at 
treating symptoms of PTSD
5. Bouso JC, Doblin R, Farré M, Alcázar MÁ, Gómez-Jarabo G. MDMA-Assisted Psychotherapy Using Low Doses in a Small Sample of Women with 
Chronic Posttraumatic Stress Disorder. Journal of Psychoactive Drugs. 2008;40(3):225-236. doi:10.1080/02791072.2008.10400637.
1. RCT of 6 participants comparing the efficacy of placebo-assisted psychotherapy to MDMA-Assisted psychotherapy in treating refractory PTSD 
symptoms
6. Mithoefer, M. C., Mithoefer, A. T., Feduccia, A. A., Jerome, L., Wagner, M., Wymer, J., ... & Doblin, R. (2018). 3, 4-methylenedioxymethamphetamine 
(MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, 
dose-response, phase 2 clinical trial. The Lancet Psychiatry, 5(6), 486-497.
1. RCT of 26 participants followed by open label crossover after 2nd “experimental session” comparing the efficacy of “active control” assisted 
psychotherapy to MDMA-Assisted psychotherapy in treating symptoms of PTSD
Study Population Therapy Compared MDMA Dosing Outcomes
1 Mean age = 31 +/- 8.8 years,83.3% male, 16.7% female, 50% White
Placebo-assisted 
psychotherapy
75 mg during first 
session, 100 mg during 
second session
LSAS
2 Mean age = 40.4 +/- 7.2 years, 17 females, 3 males, 100% White
Placebo-assisted 
psychotherapy









125 mg + 62.5 mg full 
dose, 25 mg + 12.5 mg 
“active placebo” 
CAPS scores, PDS scores, 
4 MDMA-AP: Mean age = 40.9 +/- 9.2 years, 84.4% females, 15.6% males, ethnicity 
unlisted
PE therapy: Mean age = 46.8 +/- 14.3 years, 
12.9% females, 87.1% males, ethnicity 
unlisted
PE therapy 125 mg per session, 62.5 
mg per session, 25 mg 




Cumulative effect size of primary outcomes, 
Cumulative effect size of secondary outcomes, 
cumulative dropout rates
5 Ages ranged from 29-49 years old, 100% females, ethnicity unlisted
Placebo-assisted 
psychotherapy
50 mg experimental 









6 Mean age = 37 +/- 2 years old, 27% female, 73% male, 85% white
“Active control” (30 
mg MDMA) assisted 
psychotherapy
30mg for each of the 
two sessions, 75 mg for 
each of the two sessions, 





PGTI score, GAF score, DES-II score, NEO-PI-
R
Key: RCT = randomized controlled trial; LSAS = Leibowitz Social Anxiety Scale; CAPS = Clinician Administered PTSD scale; NEO-PI-R = The Revised NEO Personality Inventory; PE therapy = Prolonged Exposure Therapy; STAI-S = The State Trait Anxiety 
Inventory, State Version; SSSPTSD = The Severity of Symptoms Scale for Post-traumatic Stress Disorder; BDI = The Beck Depression Inventory; HAM-D = The Hamilton Rating Scale; MFS III = The Modified Fear Scale; MS = The Maladjustment scale; SE/R = 
The Rosenberg Self-esteem Scale; HRS = The Hallucinogen Rating Scale; HAq = The Penn Helping Alliance Questionnaire; CAPS-IV=Clinician-Administered PTSD Scale; BDI-II=Beck Depression Inventory-II; PSQI=Pittsburgh Sleep Quality Index; PTGI=Post-
Traumatic Growth Inventory; GAF=Global Assessment of Functioning; DES-II=Dissociative Experiences Scale II
Discussion
5/6 studies reported that MDMA-Assisted psychotherapy was more 
beneficial in reducing symptoms of PTSD compared to traditional 
psychotherapy
• Strengths
• All studies were based on RCTs
• 5/6 studies reported statistically significant results (P ≤ 
0.05)
• 3 studies reported a clinically and statistically significant 
reduction in CAPS scores when compared to placebo-
assisted psychotherapy and prolonged exposure therapy, 
while 2 studies reported a significant reduction in 
SSPTSD scores and a significant reduction in Leibowitz 
Social Anxiety Scale (LSAS) scores compared to placebo-
assisted psychotherapy
• Weaknesses
• Low number of participants 
• Many of these studies have participant populations that 
are either over 75% white or fail to list the ethnicities of 
the population tested à Not a diverse patient population
• Lack of longitudinal studies
• MDMA is a Schedule I substance in the United States
Conclusion
Clinically speaking, these studies could support MDMA-Assisted 
psychotherapy being a suitable option in reducing the anxiety symptoms 
of PTSD which may be refractory to traditional psychotherapy. However
there are several gaps in the research and studies available
With such small patient populations, interpretation of these results simply 
cannot be generalized to a larger patient population and studies involving 
larger sample sizes are necessary to support the evidence of efficacy. Also, 
the differences in population demographics in these studies can make it 
difficult to support generalizing the evidence and recommending MDMA-
Assisted Psychotherapy when working with a diverse patient population. 
There is also a lack of evidence in these studies supporting the long term
effects of MDMA-Assisted psychotherapy. Finally, MDMA also remains a 
Schedule I substance in the United States, possessing and prescribing the 
substance to patients can lead to criminal charges, making large scale, 
longitudinal randomized controlled studies incredibly difficult to perform and 
fund legally.
MDMA-Assisted psychotherapy has been showing promise as an 
alternative breakthrough therapy for patients with refractory anxiety 
symptoms of PTSD. However, an increase in larger longitudinal studies 
with more diverse sample populations would be necessary before current 
practices can be changed and the therapy can be recommended for 
clinical use.  
Table 1. Comparison of study designs. MDMA-AP vs Traditional therapy
